» Articles » PMID: 37443701

Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with Ga-DOTATOC PET/CT

Overview
Specialty Radiology
Date 2023 Jul 14
PMID 37443701
Authors
Affiliations
Soon will be listed here.
Abstract

Ga-DOTATOC PET could be a noninvasive, highly sensitive, and specific technique for the challenging diagnosis of optic nerve sheath meningioma (ONSM). Our objective was to report the use and results of Ga-DOTATOC PET in suspected ONSM. Twelve subjects who underwent Ga-DOTATOC PET for suspected ONSM in our department were retrospectively included. Standardised clinical and radiological data were collected. The PET examination results were classified as positive or negative, and lesion standardised uptake values (SUV) were recorded. Ga-DOTATOC PET confirmed positive uptake in six cases (SUV > 5), leading to ONSM diagnoses followed by radiation therapy in patients with vision loss. Six Ga-DOTATOC PET scans were considered negative (SUV < 5); these comprised one case of neurosarcoidosis, one cavernous malformation, and four uncertain diagnoses, leading to further investigation. Ga-DOTATOC PET was helpful in tumour volume delineation before radiation therapy, leading to a decrease in dose exposure. Noninvasive Ga-DOTATOC PET should be performed before treating nonhistologically proven meningiomas with radiotherapy or stereotactic radiosurgery, particularly in cases of uncertain diagnosis with MRI, which characterises most ONSM cases. PET SUV thresholds to distinguish meningioma from nonspecific uptake in other lesions need to be adapted to ONSM. Ga-DOTATOC PET improves the intraorbital lesion diagnostic approach and therefore impacts therapeutic management.

References
1.
Salgues B, Graillon T, Guedj E . [Ga]Ga-DOTA-TOC PET/CT fused to MRI in post-operative evaluation of olfactory groove meningioma: a case on millimetric remnants. Eur J Nucl Med Mol Imaging. 2020; 48(1):316-317. DOI: 10.1007/s00259-020-04894-9. View

2.
Dijkstra B, Motekallemi A, den Dunnen W, Jeltema J, van Dam G, Kruyt F . SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery. Acta Neurochir (Wien). 2018; 160(8):1539-1546. PMC: 6060877. DOI: 10.1007/s00701-018-3575-z. View

3.
Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J . Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008; 27(5):334-45. DOI: 10.5414/npp27334. View

4.
Galldiks N, Albert N, Sommerauer M, Grosu A, Ganswindt U, Law I . PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol. 2017; 19(12):1576-1587. PMC: 5716194. DOI: 10.1093/neuonc/nox112. View

5.
Behling F, Fodi C, Skardelly M, Renovanz M, Castaneda S, Tabatabai G . Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential. Neurosurg Rev. 2021; 45(1):467-478. PMC: 8827401. DOI: 10.1007/s10143-021-01552-y. View